These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 519454)

  • 1. Genetic association with bladder cancer.
    Wolf H
    Br Med J; 1979 Nov; 2(6201):1366. PubMed ID: 519454
    [No Abstract]   [Full Text] [Related]  

  • 2. Genetic polymorphism and cancer susceptibility: evidence concerning acetyltransferases and cancer of the urinary bladder.
    Hein DW
    Bioessays; 1988 Dec; 9(6):200-4. PubMed ID: 3072000
    [No Abstract]   [Full Text] [Related]  

  • 3. The biochemical indices of genetic susceptibility to cancer. Acetylation phenotype and bladder cancer.
    Hanke J; Krajewska B
    Pol J Occup Med; 1988; 1(4):306-11. PubMed ID: 2979565
    [No Abstract]   [Full Text] [Related]  

  • 4. N-acetyltransferase phenotypes of bladder cancer patients in a low-risk population.
    Mommsen S; Sell A; Barfod N
    Lancet; 1982 Nov; 2(8309):1228. PubMed ID: 6128543
    [No Abstract]   [Full Text] [Related]  

  • 5. Role of N-acetyltransferase phenotype in human susceptibility to bladder carcinogenic arylamines.
    Wolf H; Lower GM; Bryan GT
    Scand J Urol Nephrol; 1980; 14(2):161-5. PubMed ID: 7209420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Significance of N-acetyltransferase phenotype in development of bladder neoplasms].
    Wolf H; Lower GM; Bryan GT
    Ugeskr Laeger; 1980 Feb; 142(6):382-5. PubMed ID: 7368384
    [No Abstract]   [Full Text] [Related]  

  • 7. [Acetylation phenotype in patients with cancer of the bladder. Preliminary report].
    Skretowicz J; Polakowski P; Jeromin L; Zasada M; Szymańska J; Krajewska B
    Med Pr; 1988; 39(4):241-5. PubMed ID: 3237058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-acetyltransferase 2 phenotype but not NAT1*10 genotype affects aminobiphenyl-hemoglobin adduct levels.
    Probst-Hensch NM; Bell DA; Watson MA; Skipper PL; Tannenbaum SR; Chan KK; Ross RK; Yu MC
    Cancer Epidemiol Biomarkers Prev; 2000 Jun; 9(6):619-23. PubMed ID: 10868698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic regulation of N-acetyltransferase in target organs of arylamine tumors: homologous expression in human and hamster bladder and colon.
    Hein DW
    Proc West Pharmacol Soc; 1991; 34():55-60. PubMed ID: 1788341
    [No Abstract]   [Full Text] [Related]  

  • 10. The role of genetic factors in bladder cancer.
    Schulte PA
    Cancer Detect Prev; 1988; 11(3-6):379-88. PubMed ID: 3390858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of NAT1 and NAT2 polymorphisms to urinary bladder cancer: significantly reduced risk in subjects with NAT1*10.
    Cascorbi I; Roots I; Brockmöller J
    Cancer Res; 2001 Jul; 61(13):5051-6. PubMed ID: 11431340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-acetyltransferase phenotype and risk in urinary bladder cancer: approaches in molecular epidemiology. Preliminary results in Sweden and Denmark.
    Lower GM; Nilsson T; Nelson CE; Wolf H; Gamsky TE; Bryan GT
    Environ Health Perspect; 1979 Apr; 29():71-9. PubMed ID: 510245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of the genotypes for N-acetyltransferases 1 and 2 with double bladder and prostate cancers in a case-comparison study.
    Wang CY; Jones RF; Debiec-Rychter M; Soos G; Haas GP
    Anticancer Res; 2002; 22(6B):3529-35. PubMed ID: 12552951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bladder cancer risk from the perspective of genetic polymorphisms in the carcinogen metabolizing enzymes.
    Antonova O; Toncheva D; Grigorov E
    J BUON; 2015; 20(6):1397-406. PubMed ID: 26854433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased expression of ESCO1 is correlated with poor patient survival and its role in human bladder cancer.
    Zhang S; Li J; Zhou G; Mu D; Yan J; Xing J; Yao Z; Sheng H; Li D; Lv C; Sun B; Hong Q; Guo H
    Tumour Biol; 2016 Apr; 37(4):5165-70. PubMed ID: 26547586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphisms for aromatic amine metabolism in humans: relevance for human carcinogenesis.
    Kadlubar FF; Butler MA; Kaderlik KR; Chou HC; Lang NP
    Environ Health Perspect; 1992 Nov; 98():69-74. PubMed ID: 1486865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The acetylator phenotype in patients with urinary bladder cancer].
    Wich H; Franke G; Grimm U; Siegmund W
    Z Urol Nephrol; 1989 Nov; 82(11):597-9. PubMed ID: 2618184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Metabolic polymorphisms and the cancer risk: the evaluation of epidemiological studies].
    Vineis P; Landi MT; Caporaso N
    Med Lav; 1992; 83(6):557-75. PubMed ID: 1296137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors.
    Kaisary A; Smith P; Jaczq E; McAllister CB; Wilkinson GR; Ray WA; Branch RA
    Cancer Res; 1987 Oct; 47(20):5488-93. PubMed ID: 3652049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic association with bladder cancer.
    Cartwright RA
    Br Med J; 1979 Sep; 2(6193):798. PubMed ID: 519209
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.